Αρχειοθήκη ιστολογίου

Αλέξανδρος Γ. Σφακιανάκης
ΩτοΡινοΛαρυγγολόγος
Αναπαύσεως 5
Άγιος Νικόλαος Κρήτη 72100
2841026182
6032607174

Τρίτη 6 Σεπτεμβρίου 2016

A Subset of Neutrophils Expressing Markers of Antigen Presenting Cells in Human Visceral Leishmaniasis

Background. Visceral leishmaniasis (VL) is a potentially fatal parasitic disease associated with fever, cachexia and impaired protective T cell responses against the parasite.

Methods. Peripheral blood leukocytes from 105 subjects with VL and healthy control subjects from the endemic region of Muzaffarpur, Bihar, India were compared using flow cytometry and RT-qPCR. Findings were correlated with clinical data.

Results. An expanded population of low density neutrophils that expressed HLA-DR, CD80 and CD86 was observed in subjects with VL. This neutrophil population contracted after successful treatment of disease. Plasma from patients with acute VL was able to induce similar high-level HLA-DR expression in neutrophils from healthy subjects. HLA-DR positive neutrophils of VL subjects did not uniquely stimulate T cell proliferation, but they did express higher PDL1 than other neutrophils, and lymphocytes of the same subjects expressed high surface PD1.

Conclusions. Patients with acute VL have expanded circulating low-density neutrophils expressing markers of antigen presentation, which diminish after treatment. Development of HLA-DR+ neutrophils is stimulated, at least in part, by components of plasma from patients with acute disease. Although we found no evidence they act as antigen presenting cells, these neutrophils expressed markers implicating a role in T cell exhaustion.



http://ift.tt/2c2Fzyx

Ebola Virus Replication and Disease Without Immunopathology in Mice Expressing Transgenes to Support Human Myeloid and Lymphoid Cell Engraftment

The study of Ebola virus (EBOV) pathogenesis in vivo has been limited to nonhuman primate models or use of an adapted virus to cause disease in rodent models. Herein we describe wild-type EBOV (Makona variant) infection of mice engrafted with human hematopoietic CD34+ stem cells (Hu-NSG™-SGM3 mice; hereafter referred to as SGM3 HuMice). SGM3 HuMice support increased development of myeloid immune cells, which are primary EBOV targets. In SGM3 HuMice, EBOV replicated to high levels, and disease was observed following either intraperitoneal or intramuscular inoculation. Despite the high levels of viral antigen and inflammatory cell infiltration in the liver, the characteristic histopathology of Ebola virus disease was not observed, and this absence of severe immunopathology may have contributed to the recovery and survival of some of the animals. Future investigations into the underlying mechanisms of the atypical disease presentation in SGM3 HuMice will provide additional insights into the immunopathogenesis of severe EBOV disease.



http://ift.tt/2ceOssc

Human infections by non-rodent associated hantaviruses in Africa

Various hantaviruses have been discovered in unconventional hosts (shrews and bats) in Africa. Up to now, it was unknown whether these viruses pose a threat for human health. Here, by use of newly established serological assays, we show evidence for shrew-borne hantavirus infections in humans from Côte d'Ivoire and Gabon.



http://ift.tt/2ceNQCY

Letter from Turco Regarding Article, "Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial".

Author: Turco, Pietro MD
Page: e179-e180


http://ift.tt/2crbXdq

Letter from Willey and Biviano Regarding Article, "Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial".

Author: Willey, Joshua Z. MD, MS; Biviano, Angelo MD
Page: e181-e182


http://ift.tt/2ciyrjC

Letter from Kosiuk et al Regarding Article, "Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial".

Author: Kosiuk, Jedrzej MD; Hindricks, Gerhard MD; Bollmann, Andreas MD, PhD
Page: e183-e184


http://ift.tt/2crb3Oa

Letter from Liu and Yang Regarding Article, "Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial".

Author: Liu, Wei MD; Yang, Xiao-jie MM
Page: e185-e186


http://ift.tt/2ciyoo0